Breast Cancer Clinical Trial
Official title:
A Single Center, Randomized, Blind, Parallel Controlled, Single Dose Pharmacokinetic Study of Recombinant Humanized Anti-HER-2 Monoclonal Antibody Injection GB221 in Comparison With Herceptin ® in Chinese Healthy Adult Volunteers
Verified date | March 2021 |
Source | Genor Biopharma Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single center, randomized, blind, parallel controlled clinical trial. The primary objective is to evaluate the single dose pharmacokinetics of recombinant Humanized anti-HER-2 monoclonal antibody injection GB221 in comparison with Herceptin ® in Chinese healthy adult volunteers. The main aim is to study the pharmacokinetic similarity between GB221 and Herceptin ®.
Status | Completed |
Enrollment | 87 |
Est. completion date | September 11, 2020 |
Est. primary completion date | September 8, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - 1. Signed informed consent form; - 2. Healthy adult volunteers aged between 18 and 45, male or female; - 3. Medical examination as required within 28 days, body mass index (BMI) 19.0 ~ 24.0, weight=50 kg for men, =45 kg for women, and= 75 kg for both; - 4. Agreed with taking reliable contraceptive measures, and no fertility planning from the beginning to the end of the study within 6 months; - 5.Subject can communicate well with the investigators and complete the study according to the study regulations. Exclusion Criteria: - 1. Pregnant or lactating women, or positive in either blood or urine pregnancy test; or unwilling to take effective contraceptive measures during the trial and within 6 months after the end of the trial at fertile age; - 2. Allergic constitution; or history of allergic to experimental drug ingredient or any drug or food or pollen; or abnormal serum immunoglobulin E (IgE) test; - 3. History of drug abuse, or positive urine test for drug; - 4. History of the central nervous system, cardiovascular system, kidney, liver, digestive system, respiratory system, metabolic system or other significant diseases. History of high blood pressure, or clinically significant systolic blood pressure=140 mmHg/diastolic blood pressure=90 mmHg; - 5. Family history of cancer, or tumor markers (male: CEA, AFP, PSA, CA-125; Female: CEA, AFP, CA-153, CA-125) positive. - 6. Participated in other clinical trials of drug or used drugs harmful to major organs within 3 months; - 7. Blood donation within 3 months; - 8. Used prescription or OTC drugs within 14 days; - 9. Left ventricular ejection fraction (LVEF) < 60%; - 10. ALT or AST > 1.5 ULN, Cr > ULN; - 11. WBC < 0.8 LLN or > 1.2 ULN; ANC < 0.8 LLN; PLT < 0.8 LLN; HGB < 0.9LLN. - 12. HBs-Ag, HCV-Ab, anti-HIV or TP-Ab positive; - 13. Anti-drug antibody (ADA) test positive; - 14.History of psychosis; - 15. History of postural hypotension; - 16. More than 5 cigarettes per day; - 17. More than 28 units of alcohol per week; Or alcohol breath test positive within 24 hours before pre-dose; - 18. History of dizziness of blood or needle; - 19. Unsuitable for other reasons. |
Country | Name | City | State |
---|---|---|---|
China | The Fifth Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangzhou |
Lead Sponsor | Collaborator |
---|---|
Genor Biopharma Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AUC0-t | compare the pharmacokinetic AUC0-t parameters of GB221 and Herceptin ® | Day 43 | |
Primary | AUC0-8 | compare the pharmacokinetic AUC0-8parameters of GB221 and Herceptin ® | Day 43 | |
Primary | Cmax | compare the pharmacokinetic Cmax parameters of GB221 and Herceptin ® | Day 43 | |
Secondary | Tmax | compare the pharmacokinetic Tmax parameters of GB221 and Herceptin ® | Day 43 | |
Secondary | t1/2 | compare the pharmacokinetic t1/2 parameters of GB221 and Herceptin ® | Day 43 | |
Secondary | CL | compare the pharmacokinetic CL parameters of GB221 and Herceptin ® | Day 43 | |
Secondary | Vd | compare the pharmacokinetic Vd parameters of GB221 and Herceptin ® | Day 43 | |
Secondary | Ke | compare the pharmacokinetic Ke parameters of GB221 and Herceptin ® | Day 43 | |
Secondary | ADA | compare the incidence of ADA in of GB221 and Herceptin ® group | Day 43 | |
Secondary | Nab | compare the incidence of Nab in of GB221 and Herceptin ® group | Day 43 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |